OMC
EVLO

Old Mission Capital’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Old Mission Capital’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-503
Closed -$138K – 1363
2021
Q2 		$138K Buy
+503
New +$127K ﹤0.01% 915

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Old Mission Capital's EVLO Position: Q3 2021 in Review

Old Mission Capital sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2021, closing a stake of 503 shares — an estimated $138K sold.

Old Mission Capital first reported a position in EVLO in Q2 2021 and held it in 1 quarter. The position peaked at $138K in Q2 2021. 64 funds tracked by Wall St. Rank hold EVLO as of Q3 2021.

  • Old Mission Capital reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Old Mission Capital sold 503 Evelo Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $138K.
  • Old Mission Capital first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Old Mission Capital's Evelo Biosciences, Inc. Common Stock position peaked at $138K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2021.

Based on Old Mission Capital's 13F filing for Q3 2021, filed 12 Nov 2021.